Ribonucleotide Reductases
"Ribonucleotide Reductases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D012264
|
| MeSH Number(s) |
D08.811.682.810
|
| Concept/Terms |
Ribonucleotide Reductases- Ribonucleotide Reductases
- Reductases, Ribonucleotide
- Ribonucleotide Reductase
- Reductase, Ribonucleotide
|
Below are MeSH descriptors whose meaning is more general than "Ribonucleotide Reductases".
Below are MeSH descriptors whose meaning is more specific than "Ribonucleotide Reductases".
This graph shows the total number of publications written about "Ribonucleotide Reductases" by people in this website by year, and whether "Ribonucleotide Reductases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribonucleotide Reductases" by people in Profiles.
-
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production. Sci Adv. 2023 05 19; 9(20):eade7236.
-
Reflections on Charlie Gard and the Best Interests Standard From Both Sides of the Atlantic Ocean. Pediatrics. 2020 08; 146(Suppl 1):S60-S65.
-
Deletion of Marek's disease virus large subunit of ribonucleotide reductase impairs virus growth in vitro and in vivo. Avian Dis. 2013 Jun; 57(2 Suppl):464-8.
-
Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007 Jun; 39(6):776-80.
-
Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet. 2003 Aug; 34(4):440-5.
-
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996 May; 52(1):42-6.